Lab services company Charles River Laboratories (NYSE:CRL) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $994.2 million. Its non-GAAP profit of $2.39 per share was 1.9% above analysts’ consensus estimates.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Charles River Laboratories has had an impressive run over the past six months as its shares have beaten the S&P 500 by 20.5%. The stock now trades at $189.18, marking a 27% gain. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Wall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
In the complex ecosystem of modern medicine, few companies carry as much institutional weight—or stir as much controversy—as Charles River Laboratories International, Inc. (NYSE: CRL). As of December 23, 2025, Charles River stands as the indispensable backbone of the global pharmaceutical industry. It is a company that has, remarkably, participated in the development of over [...]
The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Shares of lab services company Charles River Laboratories (NYSE:CRL)
jumped 2.9% in the afternoon session after BofA Securities upgraded the stock and the U.S. Securities and Exchange Commission concluded its investigation into the company with no enforcement action.
Stay updated with the movements of the S&P500 index in the middle of the day on Monday. Discover which stocks are leading as top gainers and losers in today's session.
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Shares of lab services company Charles River Laboratories (NYSE:CRL)
jumped 6.1% in the afternoon session after the company provided an encouraging business update at an investor conference, highlighting positive demand trends.
Stay updated with the movements of the S&P500 index in the middle of the day on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.
